Bayer AG (BAY.F)'s Nexavar Not Recommended by National Institute for Clinical Excellence (NICE) for Liver Cancer  
5/7/2009 7:05:52 AM

Bookmark and Share Reuters -- Britain's healthcare cost-effectiveness watchdog said on Thursday it had recommended that Bayer AG's new drug Nexavar should not be given on the state health service to patients with liver cancer.